Journal
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
Volume 60, Issue 3, Pages 233-247Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10408363.2022.2158779
Keywords
Parapneumonic pleural effusion; circulating biomarkers; diagnosis
Categories
Ask authors/readers for more resources
Parapneumonic pleural effusion (PPE) is a common complication in patients with pneumonia. Current biomarkers lack adequate performance for diagnosing and stratifying PPE, highlighting the need for further research to identify and validate novel biomarkers and their combinations for PPE management.
Parapneumonic pleural effusion (PPE) is a common complication in patients with pneumonia. Timely and accurate diagnosis of PPE is of great value for its management. Measurement of biomarkers in circulating and pleural fluid have the advantages of easy accessibility, short turn-around time, objectiveness and low cost and thus have utility for PPE diagnosis and stratification. To date, many biomarkers have been reported to be of value for the management of PPE. Here, we review the values of pleural fluid and circulating biomarkers for the diagnosis and stratification PPE. The biomarkers discussed are C-reactive protein, procalcitonin, presepsin, soluble triggering receptor expressed on myeloid cells 1, lipopolysaccharide-binding protein, inflammatory markers, serum amyloid A, soluble urokinase plasminogen activator receptor, matrix metalloproteinases, pentraxin-3 and cell-free DNA. We found that none of the available biomarkers has adequate performance for diagnosing and stratifying PPE. Therefore, further work is needed to identify and validate novel biomarkers, and their combinations, for the management of PPE.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available